Cited by 156Diabetes Treatment and ManagementAtherosclerosis and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

Open access

Ta, Nga N, Schuyler, Corinne A, Li, Yanchun, Lopes-Virella, Maria F, Huang, Yan·2011·Journal of Cardiovascular Pharmacology

DOI 10.1097/fjc.0b013e31821e5626PMC PMC3155015

Open this paper in CoChat — free account

Abstract

Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of hyperglycemia. Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis. In this study, nondiabetic and diabetic apolipoprotein E-deficient mice were treated with DPP-4 inhibitor alogliptin for 24 weeks, and atherosclerotic lesions in aortic origins were examined. Results showed that diabetes significantly increased atherosclerotic lesions, but alogliptin treatment reduced atherosclerotic lesions in diabetic mice. Metabolic studies showed that diabetes increased plasma glucose and that alogliptin treatment reduced glucose. Furthermore, immunohistochemistry study showed that diabetes increased interleukin-6 (IL-6) and IL-1β protein expression in atherosclerotic plaques, but alogliptin treatment attenuated diabetes-augmented IL-6 and IL-1β expression. In consistence with the observations from the mouse models, our in vitro studies showed that alogliptin-inhibited toll-like receptor 4 (TLR-4)-mediated upregulation of IL-6, IL-1β, and other proinflammatory cytokines by mononuclear cells. Taken together, our findings showed that alogliptin-inhibited atherosclerosis in diabetic apolipoprotein E-deficient mice and that the actions of alogliptin on both glucose and inflammation may contribute to the inhibition.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/fjc.0b013e31821e5626

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects
Dasu, M. R., Devaraj, S., Park, S., & Jialal, I. (2010) · Diabetes Care · doi:10.2337/dc09-1799 · Cited by 572
Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV
Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., Asakawa, T., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070104l · Cited by 409
Troglitazone Inhibits Formation of Early Atherosclerotic Lesions in Diabetic and Nondiabetic Low Density Lipoprotein Receptor–Deficient Mice
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S. M., Wakino, S., Noh, G. J., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 389
CD26: a surface protease involved in T-cell activation
Fleischer, B. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90316-6 · Cited by 329
Application of Photoshop-based Image Analysis to Quantification of Hormone Receptor Expression in Breast Cancer
Lehr, H., Mankoff, D. A., Corwin, D., Santeusanio, G., & Gown, A. M. (1997) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549704501112 · Cited by 308
Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control
DeFronzo, R. A., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 010 Group (2008) · Diabetes Care · doi:10.2337/dc08-1035 · Cited by 227
TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis
Michelsen, K. S., Doherty, T. M., Shah, P. K., & Arditi, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.10.5901 · Cited by 211
Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)
Ferreira, L., Teixeira‐Lemos, E., Pinto, F., Parada, B., Mega, C., Vala, H., Pinto, R. M. A., Garrido, P., Sereno, J., Fernandes, R., et al. (2010) · Mediators of Inflammation · doi:10.1155/2010/592760 · Cited by 196
Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes
Ulrich, W., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 174
Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice
Lin, R.-Y., Choudhury, R. P., Cai, W., Lu, M. M., Fallon, J. T., Fisher, E. A. A., & Vlassara, H. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00050-9 · Cited by 169

Show all 42 references

Research works printed but not linked: 1

Jungraithmayr, 31, Peptides, 585-, 591

Sorted by citations

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 255
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Zhong, J., Rao, X., & Rajagopalan, S. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.012 · Cited by 209
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis
Waumans, Y., Baerts, L., Kehoe, K., Lambeir, A., & Meester, I. D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00387 · Cited by 194
DPP4 in Cardiometabolic Disease
Zhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 190
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE −/− mouse model
Gaspari, T., Welungoda, I., Widdop, R. E., Simpson, R. W., & Dear, A. E. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164113481817 · Cited by 148
Hypoglycemic agents and potential anti-inflammatory activity
Mathews, S. T., Kothari, V. M., & Galdo, J. A. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s86917 · Cited by 133
Toll-Like Receptors in Atherosclerosis
Falck-Hansen, M., Kassiteridi, C., & Monaco, C. G. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140714008 · Cited by 128
The potential for renoprotection with incretin-based drugs
Tanaka, T., Higashijima, Y., Wada, T., & Nangaku, M. (2014) · Kidney International · doi:10.1038/ki.2014.236 · Cited by 123
The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms
Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W.-W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 113
Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation
Fuentes‐Antrás, J., Ioan, A.-M., Tuñón, J., Egido, J., & Lorenzo, Ó. (2014) · International Journal of Endocrinology · doi:10.1155/2014/847827 · Cited by 97
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Katsiki, N., & Ferrannini, E. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107723 · Cited by 91
Toll-like receptors: sensing and reacting to diabetic injury in the kidney
Lin, M., & Tang, S. C. W. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft446 · Cited by 86
Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Tomović, K., Lazarević, J., Kocic, G. M., Deljanin-Ilić, M., Anderluh, M., & Šmelcerović, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21513 · Cited by 88
Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis
Matheeussen, V., Waumans, Y., Martinet, W., Goethem, S. V., der Veken, P. V., Scharpé, S., Augustyns, K., Meyer, G. R. Y. D., & Meester, I. D. (2013) · Basic Research in Cardiology · doi:10.1007/s00395-013-0350-4 · Cited by 86
Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
Singh, A.-K., Yadav, D., Sharma, N., & Jin, J. (2021) · Pharmaceuticals · doi:10.3390/ph14060586 · Cited by 97
Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction
Esposito, G., Cappetta, D., Russo, R., Rivellino, A., Ciuffreda, L. P., Roviezzo, F., Piegari, E., Berrino, L., Rossi, F., Angelis, A. D., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13686 · Cited by 81
The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
Kim, N.-H., Yu, T., & Lee, D. H. (2014) · BioMed Research International · doi:10.1155/2014/368703 · Cited by 86
TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice
Lu, Z., Zhang, X., Li, Y., Jin, J., & Huang, Y. Q. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0338 · Cited by 78
Self-citation
DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages
Brenner, C., Franz, W.-M., Kühlenthal, S., Kuschnerus, K., Remm, F., Gross, L., Theiss, H. D., Landmesser, U., & Kränkel, N. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.044 · Cited by 80
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression
Hwang, H.-J., Jung, T. W., Kim, B.-H., Hong, H. C., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., Choi, D. S., Baik, S. H., et al. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.08.098 · Cited by 72
Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice
Terasaki, M., Nagashima, M., Nohtomi, K., Kohashi, K., Tomoyasu, M., Shinmura, K., Nogi, Y., Katayama, Y., Sato, K., Itoh, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070933 · Cited by 71
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome
Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 71
Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury
Matheeussen, V., Jungraithmayr, W., & Meester, I. D. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.012 · Cited by 66
Dipeptidyl Peptidase‐4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation
Ikedo, T., Minami, M., Kataoka, H., Hayashi, K., Nagata, M., Fujikawa, R., Higuchi, S., Yasui, M., Aoki, T., Fukuda, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004777 · Cited by 64
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 62
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Panchapakesan, U., Mather, A., & Pollock, C. A. (2012) · Clinical Science · doi:10.1042/cs20120167 · Cited by 57
Targeting Immune Senescence in Atherosclerosis
Vellasamy, D. M., Lee, S.-J., Goh, K. W., Goh, B. H., Tang, Y.-Q., Ming, L. C., & Yap, W. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113059 · Cited by 63
Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways
El-Sahar, A. E., Shiha, N. A., Sayed, N. S. E., & Ahmed, L. A. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa078 · Cited by 58
The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
Ren, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
DPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 57
Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 56
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)‐TIMI 53 trial
Mosenzon, O., Raz, I., Scirica, B. M., Hirshberg, B., Stahre, C., Steg, P. G., Davidson, J. A., Öhman, P., Price, D. L., Frederich, B., et al. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2413 · Cited by 51
Dipeptidyl peptidase-4 inhibition and vascular repair by mobilization of endogenous stem cells in diabetes and beyond
Fadini, G. P., & Avogaro, A. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.007 · Cited by 52
DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice
Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Henry-Smith, C. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165933 · Cited by 50
“Importantly, in some studies, the positive effects of these drugs are completely independent of DPP4’s canonical role in glucose metabolism (13), highlighting the need to explore other mechanisms by which DPP4 functions in atherosclerotic vascular diseases.”
DPP-4 Inhibitors as Therapeutic Modulators of Immune Cell Function and Associated Cardiovascular and Renal Insulin Resistance in Obesity and Diabetes
Aroor, A. R., McKarns, S. C., Nistala, R., DeMarco, V. G., Gardner, M., Garcia‐Touza, M., Whaley‐Connell, A. T., & Sowers, J. R. (2013) · Cardiorenal Medicine · doi:10.1159/000348756 · Cited by 49
Anti‐inflammatory effects of linagliptin in hemodialysis patients with diabetes
Nakamura, Y., Tsuji, M., Hasegawa, H., Kimura, K., Fujita, K., Inoue, M., Shimizu, T., Gotoh, H., Goto, Y., Inagaki, M., et al. (2014) · Hemodialysis International · doi:10.1111/hdi.12127 · Cited by 46
Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence
Kawanami, D., Matoba, K., Sango, K., & Utsunomiya, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081223 · Cited by 46
Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
Király, K. P., Kozsurek, M., Lukácsi, E., Barta, B., Alpár, A., Balázsa, T., Fekete, C., Szabon, J., Helyes, Z., Bölcskei, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21799-8 · Cited by 46
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 45
Atherosclerosis
Aviram, M. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283513594 · Cited by 43
Animal Models of Diabetic Macrovascular Complications: Key Players in the Development of New Therapeutic Approaches
Heinonen, S. E., Genové, G., Bengtsson, E., Hübschle, T., Åkesson, L., Hiss, K., Benardeau, A. M., Ylä‐Herttuala, S., Jönsson‐Rylander, A., & Gomez, M. F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/404085 · Cited by 44
Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice
Akita, K., Isoda, K., Shimada, K., & Daida, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001469 · Cited by 42
The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
Wang, M.-T., Lin, S., Tang, P., Hung, W.-T., Cheng, C.-C., Yang, J.-S., Chang, H., Liu, C., Mar, G.-Y., & Huang, W. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0572-0 · Cited by 41
The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice
Waumans, Y., Vliegen, G., Maes, L., Rombouts, M., Declerck, K., der Veken, P. V., Berghe, W. V., Meyer, G. R. Y. D., Schrijvers, D. M., & Meester, I. D. (2015) · Inflammation · doi:10.1007/s10753-015-0263-5 · Cited by 39
Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 37
Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?
Desouza, C. V. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.04.007 · Cited by 36
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Rizzo, M., Nikolić, D., Banach, M., Patti, A. M., Montalto, G., & Rizvi, A. A. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612819666131206102255 · Cited by 35
Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 35
The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
Aroor, A. R., Manrique‐Acevedo, C., & DeMarco, V. G. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0704-1 · Cited by 37
A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
Terasaki, M., Yashima, H., Mori, Y., Saito, T., Matsui, T., Hiromura, M., Kushima, H., Osaka, N., Ohara, M., Fukui, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134811 · Cited by 33
Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors
Nakamura, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.840 · Cited by 35
Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients
Chang, C. C., Chen, Y., Hsu, C., Su, Y., Chiu, C.-C., Leu, H., Huang, P., Chen, J., & Lin, S. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.10.016 · Cited by 34
Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages
Hiromura, M., Nohtomi, K., Mori, Y., Kataoka, H., Sugano, M., Ohnuma, K., Kuwata, H., & Hirano, T. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.016 · Cited by 34
Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning
Rameshrad, M., Razavi, B. M., Ferns, G. A. A., & Hosseinzadeh, H. (2019) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-019-00238-7 · Cited by 34
Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
Shigematsu, E. (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1889w · Cited by 33
Understanding the intricacies of cellular senescence in atherosclerosis: Mechanisms and therapeutic implications
Ali, I., Zhang, H., Zaidi, S. A. A., & Zhou, G. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102273 · Cited by 36
The potential effects of DPP‐4 inhibitors on cardiovascular system in COVID‐19 patients
Du, H., Wang, D. W., & Chen, C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15674 · Cited by 32
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Koška, J., Sands, M. A., Burciu, C., & Reaven, P. D. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114562411 · Cited by 31
Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials
Balakumar, P., & Dhanaraj, S. A. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.009 · Cited by 31
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease
Remm, F., Franz, W., & Brenner, C. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv044 · Cited by 31
The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes
Lee, T.-I., Kao, Y.-H., Chen, Y.-C., Huang, J.-H., Hsu, M., & Chen, Y.-J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.08.051 · Cited by 30
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice
Kohashi, K., Hiromura, M., Mori, Y., Terasaki, M., Watanabe, T., Kushima, H., Shinmura, K., Tomoyasu, M., Nagashima, M., & Hirano, T. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31997 · Cited by 30
GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells
Hu, Y., Liu, H. B., Simpson, R. W., & Dear, A. E. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2290-8 · Cited by 29
DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation
Hu, X., Liu, S., Liu, X., Zhang, J., Liang, Y. J., & Yan, L. (2016) · Endocrine · doi:10.1007/s12020-016-1073-8 · Cited by 29
miR-29b Mediates the Chronic Inflammatory Response in Radiotherapy-Induced Vascular Disease
Eken, S. M., Christersdottir, T., Winski, G., Sangsuwan, T., Jin, H. H., Chernogubova, E., Pirault, J., Sun, C., Simon, N. L., Winter, H., et al. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.10.006 · Cited by 32
The Anti-Inflammatory Effect of Novel Antidiabetic Agents
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K., & Tousoulis, D. (2022) · Life · doi:10.3390/life12111829 · Cited by 30
Increased Plasma Dipeptidyl Peptidase-4 Activities in Patients with Coronary Artery Disease
Yang, G., Li, Y.-Z., Cui, L., Jiang, H., Li, X., Jin, C., Jin, D., Zhao, G., Jin, J., Sun, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163027 · Cited by 25
Self-citation
Alogliptin inhibits IL-1β-induced inflammatory response in fibroblast-like synoviocytes
Guo, Q., Zhang, S., Huang, J., & Liu, K. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106372 · Cited by 25
Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease
Rroji, M., & Spasovski, G. B. (2024) · Biomedicines · doi:10.3390/biomedicines12030657 · Cited by 27
DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives
Bonora, E., & CIGOLINI, M. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.03.002 · Cited by 25
Coronavirus Receptors as Immune Modulators
Devarakonda, C. K. V., Meredith, E. K., Ghosh, M., & Shapiro, L. H. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001062 · Cited by 22
Incretin hormones as immunomodulators of atherosclerosis
Alonso, N., Julián, M. T., Puig‐Domingo, M., & Vives‐Pi, M. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00112 · Cited by 24
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
Lim, S. W., Jin, J. Z., Jin, L. G., Jin, J., & Li, C. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.759 · Cited by 25
Hypertension in diabetes care: emerging roles of recent hypoglycemic agents
Tanaka, A., & Node, K. (2021) · Hypertension Research · doi:10.1038/s41440-021-00665-7 · Cited by 21
Emerging Roles of Dipeptidyl Peptidase 4 Inhibitors: Anti-Inflammatory and Immunomodulatory Effect and Its Application in Diabetes Mellitus
Yang, L., Yuan, J., & Zhou, Z. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.01.008 · Cited by 21
RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy
Olejarz, W., Łacheta, D., Głuszko, A., Migacz, E., Kukwa, W., Szczepański, M. J., Tomaszewski, P., & Nowicka, G. (2018) · BioMed Research International · doi:10.1155/2018/7675286 · Cited by 21
Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice
Lin, C.-P., Huang, P., Chen, C., Wu, M., Chen, J.-S., Chen, J., & Lin, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97361-w · Cited by 20
Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosis—A review
Singh, T. P., Vangaveti, V., & Malabu, U. H. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.005 · Cited by 20
Potential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
Iwakura, T., Fukasawa, H., Kitamura, A., Ishibuchi, K., Yasuda, H., & Furuya, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229377 · Cited by 19
Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
Katakami, N., Mita, T., Yoshii, H., Onuma, T., Kaneto, H., Osonoi, T., Shiraiwa, T., Kosugi, K., Umayahara, Y., Yamamoto, T., et al. (2013) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.18333 · Cited by 18
Alogliptin benzoate for management of type 2 diabetes
Saisho, Y. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s68564 · Cited by 18
Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes
Li, B., Luo, Y., Tian, F., Chen, Y., Tian, J., Ding, Y., Mei, Z., Li, J., Zhang, Y.-Q., & Shi, W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.015 · Cited by 17
Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential anti-atherogenic properties
Kutoh, E., Kaneoka, N., & Hirate, M. (2014) · Endocrine Research · doi:10.3109/07435800.2014.952743 · Cited by 17
Linagliptin inhibits lipopolysaccharide-induced inflammation in human U937 monocytes
Yamadera, S., Nakamura, Y., Inagaki, M., Kenmotsu, S., Nohara, T., Sato, N., Oguchi, T., Tsuji, M., Ohsawa, I., Gotoh, H., et al. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0071-z · Cited by 17
Vildagliptin, a DPP-4 Inhibitor, Attenuates Endothelial Dysfunction and Atherogenesis in Nondiabetic Apolipoprotein E-Deficient Mice
Aini, K., Fukuda, D., Tanaka, K., Higashikuni, Y., Hirata, Y., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2019) · International Heart Journal · doi:10.1536/ihj.19-117 · Cited by 18
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes
Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 16
Alogliptin benzoate for the treatment of type 2 diabetes
Seino, Y., & Yabe, D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.898750 · Cited by 15
Long-term effects of different hypoglycemic drugs on carotid intima-media thickness progression: a systematic review and network meta-analysis
Lv, Q., Yang, Y., Lv, Y., Wu, Q., Hou, X.-Z., Li, L., Ye, X., Yang, C., & Wang, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1403606 · Cited by 18
Targeting senescent cells in atherosclerosis: Pathways to novel therapies
Tian, Y., Shao, S., Feng, H., Zeng, R., Li, S., & Zhang, Q. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102502 · Cited by 15
Saxagliptin protects against hypoxia-induced damage in H9c2 cells
Zhang, L., Qi, X., Zhang, G., Zhang, Y., & Tian, J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108864 · Cited by 14
Diabetes medications and cardiovascular outcome trials: Lessons learned
Patel, K. V., Rocha, N. D. A., & McGuire, D. K. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84gr.17006 · Cited by 14
Consumption of Amaranth Induces the Accumulation of the Antioxidant Protein Paraoxonase/Arylesterase 1 and Modulates Dipeptidyl Peptidase IV Activity in Plasma of Streptozotocin-Induced Hyperglycemic Rats
Velarde‐Salcedo, A. J., Regalado-Rentería, E., Velarde-Salcedo, R., Juárez-Flores, B. I., Barrera-Pacheco, A., de Mejı́a, E. G., & de la Rosa, A. P. B. (2017) · Lifestyle Genomics · doi:10.1159/000486482 · Cited by 14
Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
Dai, Y., Dai, D., Mercanti, F., Ding, Z., Wang, X., & Mehta, J. L. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0496-4 · Cited by 13
Potential Impact of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Pathophysiology in Type 2 Diabetes Mellitus
Davidson, M. H. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2756 · Cited by 13
Effects of vildagliptin on wound healing and markers of inflammation in patients with type 2 diabetic foot ulcer: a prospective, randomized, double-blind, placebo-controlled, single-center study
Vangaveti, V., Jhamb, S., Hayes, O., Goodall, J., Bulbrook, J., Robertson, K., Biroš, E., Sangla, K. S., & Malabu, U. H. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00938-2 · Cited by 13
The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
Green, J. B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2566 · Cited by 12

Authors: Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y.
Affiliations: Medical University of South Carolina (US)
Corresponding author: Huang, Yan
ORCID: Lopes-Virella, Maria F
Huang, Yan
Venue: Journal of Cardiovascular Pharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-08
Volume: 58
Issue: 2
Pages: 157-166
ISSN: 0160-2446 (ISSN-L)
DOI: 10.1097/fjc.0b013e31821e5626
PMC: PMC3155015
OpenAlex: W2059903872
Cited by: 156
References: 42
Citations by year: 2025: 2 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 13 · 2017: 10 · 2016: 16 · 2015: 22 · 2014: 17 · 2013: 23 · 2012: 13
FWCI: 13.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Cardiovascular Pharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Dental and Craniofacial Research (R01DE016353, DE016353)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: alogliptin, DPP-4 inhibitors, atherosclerosis, diabetes mellitus, ApoE-deficient mice, interleukin-6, IL-1β, TLR4, inflammation, glucose, mononuclear cells, aortic atherosclerotic lesions
MeSH terms: Interleukin-6 Inhibitors, Animals, Apolipoproteins E, Blood Glucose, Cholesterol, Diabetes Mellitus, Experimental, Enzyme-Linked Immunosorbent Assay, Humans, Male, Piperidines, Triglycerides, Uracil, Mice, Knockout, Dipeptidyl Peptidase 4, U937 Cells, Atherosclerosis, Mice, Interleukin-1beta, Dipeptidyl-Peptidase IV Inhibitors, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks